Company news

Vanda Pharmaceuticals Inc. news in 2024

Vanda Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.

View company

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

December 19, 2024

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

November 11, 2024

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 5, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

October 29, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

October 13, 2024

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

September 18, 2024

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

September 10, 2024

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

September 3, 2024

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference

August 28, 2024

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results

July 30, 2024

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

July 25, 2024

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

June 30, 2024

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

June 18, 2024

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

June 12, 2024

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

June 5, 2024

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

May 29, 2024

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

May 29, 2024

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

May 28, 2024

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders

May 23, 2024

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness

May 14, 2024

Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results

May 7, 2024

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024

April 29, 2024

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation

April 21, 2024

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

April 16, 2024

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

April 16, 2024

Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

April 1, 2024

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

March 5, 2024

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 6, 2024

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024

January 30, 2024

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

January 30, 2024

Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024

January 28, 2024

Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepato...

January 24, 2024

Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.

January 24, 2024

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

January 22, 2024

Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration

January 18, 2024

Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry

January 16, 2024

Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs

January 11, 2024

Calls in 2024

Decks in 2024